Growth Metrics

Bionano Genomics (BNGO) Accounts Payables (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Accounts Payables for 9 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 19.71% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 19.71% year-over-year, with the annual reading at $5.6 million for FY2025, 19.71% down from the prior year.
  • Accounts Payables hit $5.6 million in Q4 2025 for Bionano Genomics, down from $6.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $15.8 million in Q1 2023 to a low of $2.2 million in Q1 2021.
  • Historically, Accounts Payables has averaged $8.6 million across 5 years, with a median of $8.3 million in 2021.
  • Biggest five-year swings in Accounts Payables: surged 267.54% in 2021 and later tumbled 43.39% in 2024.
  • Year by year, Accounts Payables stood at $10.8 million in 2021, then grew by 16.39% to $12.5 million in 2022, then dropped by 17.15% to $10.4 million in 2023, then tumbled by 32.95% to $7.0 million in 2024, then decreased by 19.71% to $5.6 million in 2025.
  • Business Quant data shows Accounts Payables for BNGO at $5.6 million in Q4 2025, $6.0 million in Q3 2025, and $6.2 million in Q2 2025.